News
HRGN
5.30
-6.19%
-0.35
Weekly Report: what happened at HRGN last week (1120-1124)?
Weekly Report · 1d ago
Weekly Report: what happened at HRGN last week (1113-1117)?
Weekly Report · 11/20 11:16
Harvard Apparatus Regenerative Technology GAAP EPS of -$0.12
Harvard apparatus regenerative technology reports q3 gaap eps of -$0.12. The company had operating cash and short-term investments on-hand as of september 30, 2023 of $1.5 million. The company posted a gaap loss of $0.11 per share.
Seeking Alpha · 11/13 22:45
Weekly Report: what happened at HRGN last week (1106-1110)?
Weekly Report · 11/13 11:08
Weekly Report: what happened at HRGN last week (1030-1103)?
Weekly Report · 11/06 11:13
Weekly Report: what happened at HRGN last week (1023-1027)?
Weekly Report · 10/30 11:31
Weekly Report: what happened at HRGN last week (1016-1020)?
Weekly Report · 10/23 11:20
Weekly Report: what happened at HRGN last week (1009-1013)?
Weekly Report · 10/16 11:17
Weekly Report: what happened at HRGN last week (1002-1006)?
Weekly Report · 10/09 11:22
Weekly Report: what happened at HRGN last week (0925-0929)?
Weekly Report · 10/02 11:19
Weekly Report: what happened at HRGN last week (0918-0922)?
Weekly Report · 09/25 11:24
Weekly Report: what happened at HRGN last week (0911-0915)?
Weekly Report · 09/18 11:17
Weekly Report: what happened at HRGN last week (0904-0908)?
Weekly Report · 09/11 11:16
Weekly Report: what happened at HRGN last week (0828-0901)?
Weekly Report · 09/05 02:47
Weekly Report: what happened at HRGN last week (0821-0825)?
Weekly Report · 08/28 11:22
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
PR Newswire · 08/21 13:00
Harvard Apparatus Regenerative Technology GAAP EPS of -$0.19
Seeking Alpha · 08/14 15:06
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
PR Newswire · 08/09 18:54
Biostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)
PR Newswire · 07/20 13:00
More
Webull provides a variety of real-time HRGN stock news. You can receive the latest news about Harvard Apparatus Regenerative Technology Inc. through multiple platforms. This information may help you make smarter investment decisions.
About HRGN
Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.